Fletikumab (NNC0109-0012) (INN[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis[2] that targets IL-20.
[3] This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.
This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.